KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Deferred Taxes (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Deferred Taxes data on record, last reported at $1.5 million in Q4 2025.

  • For Q4 2025, Deferred Taxes rose 475.0% year-over-year to $1.5 million; the TTM value through Dec 2025 reached -$4.0 million, up 27.27%, while the annual FY2025 figure was -$4.0 million, 27.27% up from the prior year.
  • Deferred Taxes reached $1.5 million in Q4 2025 per EBS's latest filing, up from -$10.2 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $45.4 million in Q4 2021 and bottomed at -$51.6 million in Q4 2022.
  • Average Deferred Taxes over 5 years is -$50000.0, with a median of -$300000.0 recorded in 2024.
  • Peak YoY movement for Deferred Taxes: surged 2170.0% in 2021, then tumbled 6850.0% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at $45.4 million in 2021, then crashed by 213.66% to -$51.6 million in 2022, then surged by 89.92% to -$5.2 million in 2023, then skyrocketed by 92.31% to -$400000.0 in 2024, then skyrocketed by 475.0% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $1.5 million in Q4 2025, -$10.2 million in Q3 2025, and -$13.9 million in Q2 2025.